Cargando…
First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
BACKGROUND: In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India). MATERIALS AND METHODS: A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to Novem...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512594/ https://www.ncbi.nlm.nih.gov/pubmed/34643745 http://dx.doi.org/10.1007/s00059-021-05069-4 |
_version_ | 1784583032152260608 |
---|---|
author | Akyüz, Ali Rıza Konuş, Ali Hakan Çırakoğlu, Ömer Faruk Şahin, Sinan Kul, Selim Korkmaz, Levent |
author_facet | Akyüz, Ali Rıza Konuş, Ali Hakan Çırakoğlu, Ömer Faruk Şahin, Sinan Kul, Selim Korkmaz, Levent |
author_sort | Akyüz, Ali Rıza |
collection | PubMed |
description | BACKGROUND: In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India). MATERIALS AND METHODS: A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study. RESULTS: The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days. CONCLUSION: Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves. VIDEO ONLINE: The online version of this article contains a video. The article and the video are available online (10.1007/s00059-021-05069-4). The video can be found in the article back matter as “Electronic Supplementary Material”. |
format | Online Article Text |
id | pubmed-8512594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-85125942021-10-13 First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study Akyüz, Ali Rıza Konuş, Ali Hakan Çırakoğlu, Ömer Faruk Şahin, Sinan Kul, Selim Korkmaz, Levent Herz Original Articles BACKGROUND: In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India). MATERIALS AND METHODS: A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study. RESULTS: The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days. CONCLUSION: Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves. VIDEO ONLINE: The online version of this article contains a video. The article and the video are available online (10.1007/s00059-021-05069-4). The video can be found in the article back matter as “Electronic Supplementary Material”. Springer Medizin 2021-10-13 2022 /pmc/articles/PMC8512594/ /pubmed/34643745 http://dx.doi.org/10.1007/s00059-021-05069-4 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Articles Akyüz, Ali Rıza Konuş, Ali Hakan Çırakoğlu, Ömer Faruk Şahin, Sinan Kul, Selim Korkmaz, Levent First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study |
title | First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study |
title_full | First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study |
title_fullStr | First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study |
title_full_unstemmed | First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study |
title_short | First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study |
title_sort | first experiences with a new balloon-expandable myval transcatheter aortic valve: a preliminary study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512594/ https://www.ncbi.nlm.nih.gov/pubmed/34643745 http://dx.doi.org/10.1007/s00059-021-05069-4 |
work_keys_str_mv | AT akyuzalirıza firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy AT konusalihakan firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy AT cırakogluomerfaruk firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy AT sahinsinan firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy AT kulselim firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy AT korkmazlevent firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy |